Ocean Biomedical, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OCEA research report →
Price Chart
About the company
Ocean Biomedical, Inc. operates as a biopharmaceutical firm committed to identifying and advancing novel therapeutic solutions for various medical challenges, including cancer, fibrotic disorders, infectious illnesses, and inflammation. The company's pipeline includes the development of both mono-specific and bi-specific humanized monoclonal antibodies (mAbs).
- CEO
- Inderjote Kathuria
- IPO
- 2021
- Employees
- 7
- HQ
- Providence, RI, US
Get TickerSpark's AI analysis on OCEA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $237.27K
- P/E
- -0.00
- PEG
- 0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -2.24
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 3.50%
- ROIC
- 22.76%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-3,798,000
- Net Income
- $-3,301,000+0.0%
- EPS
- $-0.12+0.0%
- OCF Growth
- +55.7%
- FCF Growth
- +55.7%
- 52W High
- $0.01
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -0.52
- RSI (14)
- 51
- Avg Volume
- 65.46K
No earnings-call transcripts are available for OCEA yet.
- Free Float
- 89.7%
- Shares Outstanding
- 232.37M
- Float Shares
- 208.41M
of shares held by institutions
23 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock Inc. | 99.88K | ▼ 371.07K |
| Cohen & Co Financial Management, LLC | 59.72K | ▼ 4.54K |
| Ayrton Capital LLC | 13.35K | ▲ 13.35K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 2, 23 | KATHURIA CHIRINJEEV | other | 500,000 |
| Oct 2, 23 | KATHURIA CHIRINJEEV | other | 500,000 |
| Mar 22, 23 | AJJARAPU SURENDRA K | other | 1,050,000 |
| Feb 28, 23 | AJJARAPU SURENDRA K | other | 21,252 |
| Mar 22, 23 | AJJARAPU SURENDRA K | other | 1,050,000 |
| Feb 28, 23 | AJJARAPU SURENDRA K | other | 21,252 |
| Feb 14, 23 | AJJARAPU SURENDRA K | buy | 5,411,000 |
| Feb 14, 23 | AJJARAPU SURENDRA K | other | 5,411,000 |
| Feb 28, 23 | AJJARAPU SURENDRA K | other | 2,625,000 |
| Feb 28, 23 | AJJARAPU SURENDRA K | other | 1,291,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our OCEA coverage
Recent articles, reports, and earnings notes.
No research on OCEA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OCEA report →Ocean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for FDA Alignment on Next-Stage Development
globenewswire.com · Feb 10
Ocean Biomedical Advances Malaria Vaccine Research with New NIH Funding and Expedited Development Pathway
globenewswire.com · Jan 29
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
globenewswire.com · Nov 22
Ocean Biomedical, Inc. Announces Receipt of Nasdaq Staff Determination Letter
globenewswire.com · Oct 22
Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical (NASDAQ: OCEA) sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors.
globenewswire.com · Oct 15
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling Responses
globenewswire.com · Oct 1
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company's Malaria Treatment and Prevention Platforms
globenewswire.com · Aug 27
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
globenewswire.com · Aug 23
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.